These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 7577479)

  • 21. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
    Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
    Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.
    Robertson JF; Bates K; Pearson D; Blamey RW; Nicholson RI
    Br J Cancer; 1992 May; 65(5):727-30. PubMed ID: 1534019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients-The role of p53.
    Rahko E; Blanco G; Bloigu R; Soini Y; Talvensaari-Mattila A; Jukkola A
    Breast; 2006 Feb; 15(1):69-75. PubMed ID: 16005229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy.
    Gee JM; Robertson JF; Ellis IO; Willsher P; McClelland RA; Hoyle HB; Kyme SR; Finlay P; Blamey RW; Nicholson RI
    Int J Cancer; 1994 Dec; 59(5):619-28. PubMed ID: 7960234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
    Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
    Yamashita H; Toyama T; Nishio M; Ando Y; Hamaguchi M; Zhang Z; Kobayashi S; Fujii Y; Iwase H
    Breast Cancer Res; 2006; 8(4):R48. PubMed ID: 16869955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.
    Shimizu D; Ishikawa T; Tanabe M; Sasaki T; Ichikawa Y; Chishima T; Endo I
    Breast Cancer; 2014 Sep; 21(5):557-62. PubMed ID: 23184499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
    Wright C; Nicholson S; Angus B; Sainsbury JR; Farndon J; Cairns J; Harris AL; Horne CH
    Br J Cancer; 1992 Jan; 65(1):118-21. PubMed ID: 1346366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
    Bergman L; Beelen ML; Gallee MP; Hollema H; Benraadt J; van Leeuwen FE
    Lancet; 2000 Sep; 356(9233):881-7. PubMed ID: 11036892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
    J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.
    Coates AS; Millar EK; O'Toole SA; Molloy TJ; Viale G; Goldhirsch A; Regan MM; Gelber RD; Sun Z; Castiglione-Gertsch M; Gusterson B; Musgrove EA; Sutherland RL
    Breast Cancer Res; 2012 Nov; 14(6):R143. PubMed ID: 23127292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
    Muss HB; Wells HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Powell BL
    J Clin Oncol; 1988 Jul; 6(7):1098-106. PubMed ID: 3292710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
    Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
    Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
    Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
    Tiezzi DG; Andrade JM; Ribeiro-Silva A; Zola FE; Marana HR; Tiezzi MG
    BMC Cancer; 2007 Feb; 7():36. PubMed ID: 17324279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
    Elledge RM; Green S; Howes L; Clark GM; Berardo M; Allred DC; Pugh R; Ciocca D; Ravdin P; O'Sullivan J; Rivkin S; Martino S; Osborne CK
    J Clin Oncol; 1997 May; 15(5):1916-22. PubMed ID: 9164202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
    Clarke RB; Laidlaw IJ; Jones LJ; Howell A; Anderson E
    Br J Cancer; 1993 Mar; 67(3):606-11. PubMed ID: 8439511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.